Aurobindo Pharma rose 0.95% to Rs 319.05 at 11:52 IST on BSE, after the company said it has secured tentative approval from US Food & Drug Administration to manufacture and market Abacavir Sulphate/Lamivudine tablets.
The company made this announcement during trading hours today, 8 September 2008.
The stock hit a high of Rs 327 and a low of Rs 317 so far during the day. The stock has a 52-week high of Rs 646 on 6 September 2007 and a 52-week low of Rs 233 on 22 January 2008.
The company’s current equity is Rs 26.88. Face value per share is Rs 5.
The current price of Rs 319.05 discounts Q1 June 2008 annualized EPS of Rs 29.67, by a PE multiple of 10.75.
Aurobindo Pharma combines 600-miligram (mg) strength of Abacavir Sulfate and 300 mg strength of Lamivudine into one tablet, whose branded product name is Epzicom.
The drug has been reviewed under the President’s Emergency Plan for AIDS Relief (PEPFAR).
On 11 August 2008, Aurobindo Pharma received final approval from US Food & Drug Administration (USFDA) for Cefazolin
On 5 August 2008, the company secured final approval from USFDA to manufacture and market Alendronate sodium tablets in multiple strengths.
Aurobindo Pharma’s net profit fell 31.9% to Rs 39.87 crore on 34.9% increase in net sales to Rs 647.23 crore in Q1 June 2008 over Q1 June 2007.
Aurobindo Pharma is engaged in developing, manufacturing and marketing active pharmaceutical ingredients, intermediates and generic formulations.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment